ZLDPF:OTC-Zealand Pharma A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 86.77

Change

+0.61 (+0.70)%

Market Cap

USD 5.24B

Volume

150.00

Analyst Target

USD 36.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NONOF Novo Nordisk A/S

+0.55 (+0.45%)

USD 564.56B
CMXHF CSL Limited

+3.86 (+2.17%)

USD 89.03B
CSLLY CSL Ltd

+0.63 (+0.69%)

USD 84.45B
UCBJF UCB SA

N/A

USD 25.40B
UCBJY UCB SA ADR

-0.06 (-0.10%)

USD 24.49B
ARGNF argenx SE

N/A

USD 22.81B
GNMSF Genmab A/S

-12.67 (-4.27%)

USD 18.12B
WXXWY WuXi Biologics (Cayman) Inc

-0.10 (-2.69%)

USD 7.17B
WXIBF WuXi Biologics

N/A

USD 7.17B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 6.76B

ETFs Containing ZLDPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 55.92% 87% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.92% 87% B+ 90% A-
Trailing 12 Months  
Capital Gain 156.15% 93% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 156.15% 93% A 95% A
Trailing 5 Years  
Capital Gain 530.14% 96% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 530.14% 96% N/A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.51% 68% D+ 74% C
Dividend Return 38.51% 68% D+ 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 76.30% 52% F 38% F
Risk Adjusted Return 50.46% 96% N/A 87% B+
Market Capitalization 5.24B 97% N/A 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector